Table 1: Summary of EGFR inhibitors in recurrent or metastatic head and neck squamous cell carcinoma.

TrialLine of treatmentPhaseNo. of patientsMedicationOverall responseMedian OS (mo)Median PFS (mo)

Monoclonal antibodies

E5397 Burtness et al. [45]FirstIII117Cisplatin versus cisplatin/cetuximab10% versus 26% ( 𝑃 0.03)8 versus 9.2 ( 𝑃 0.21) 2.7 versus 4.2 ( 𝑃 0.09)
Vermorken et al. [39]Second (platinum refractory)II103Cetuximab13%6
EXTREME Vermorken and Specenier [51]FirstIII442Platinum-based versus platin + cetuximab20% versus 36% ( 𝑃 < 0 . 0 1 )7.4 versus 10.1 ( 𝑃 0.04)3.3 versus 5.6 ( 𝑃 < 0 . 0 0 1 )
SPECTRUM Vermorken et al. [49]FirstIII657Cis/5FU versus Cis/5FU + panitumumab25% versus 36%9 versus 11.1 ( 𝑃 0.14)4.6 versus 5.8 ( 𝑃 0.004)
Zalute Machiels et al. [52]Second after platinumIII286Zalutumumab versus support or methotrexate1.1 and versus 1.1%6.7 versus 5.2 ( 𝑃 0.065)9.9 versus 8.4 ( 𝑃 0.001)
Herbst et al. [42]SecondII132Cis/cetuximab after progression on cis26%6.1 and 4.3
Hitt et al. [40]SecondII46Paclitaxel + cetuximab60%5.6
Baselga et al. [44]SecondII96Cetuximab + platinum10%6.12.8

Tyrosine kinase inhibitors

IMEX Stewart et al. [53]Second after platinum/no platinumIII486Gefitinib 250 versus gefitinib 500 versus methotrexate2.7% versus 7.6% versus 3.9%5.6 versus 6 versus 6.7
E1302 Argiris et al. [54]AnyIII270Docetaxel versus docetaxel + gefitinib 2506% versus 12% ( 𝑃 0.21)6.18 versus 6.83 ( 𝑃 0.97)2.2 versus 3.35 ( 𝑃 0.18)
BIBW2992 Seiwert et al. [55]After platinumIII124Afatinib versus cetuximab22% versus 13%3.75 versus 2.35
Siu et al. [56]FirstI/II51Erlotinib + cis21%7.93.3
Cohen et al. [57]SecondI/II48Erlotinib + bevacizumab14.5%7.14.1
Cohen et al. [58]First and secondII52Gefitinib10.6%8.13.4